Target Name: OFD1
NCBI ID: G8481
Review Report on OFD1 Target / Biomarker Content of Review Report on OFD1 Target / Biomarker
OFD1
Other Name(s): Joubert syndrome type 10 | 71-7A | OFD1 variant 1 | Oral-facial-digital syndrome 1 protein (isoform 1) | retinitis pigmentosa 23 (X-linked recessive) | CXorf5 | Protein 71-7A | MGC117040 | OFD1_HUMAN | oral-facial-digital syndrome 1 protein | JBTS10 | Centriole and centriolar satellite protein OFD1 | MGC117039 | RP23 | OFD1 centriole and centriolar satellite protein | SGBS2 | protein 71-7A | OFD1 centriole and centriolar satellite protein, transcript variant 1

Treating OFD1: Understanding The Symptoms and Treatment Options

OFD1 (Opposable Fingertip) Deformity is a rare genetic disorder that is characterized by the fusion of two fingers, resulting in an abnormal position of the fingers on the hand. This condition is often referred to as \"Joubert syndrome type 10\" or \"finger fusion syndrome.\"

The exact cause of OFD1 is not known, but it is thought to be a genetic mutation that affects the development of cartilage between the fingers. This mutation can cause the cells in the affected area to grow and develop in an abnormal way, leading to the fusion of the fingers.

OFD1 can cause a range of symptoms, including difficulty gripping objects, numbness and tingling in the affected fingers, and deformities in the hand. The severity of the symptoms can vary greatly depending on the individual affected by the condition.

Despite the challenges it poses, OFD1 is a relatively uncommon disorder, and many people are able to lead happy and fulfilling lives without any significant impact on their daily lives. However, for those who are affected by the condition, there are a few treatment options available to help manage their symptoms.

One of the main treatment options for OFD1 is surgery. In most cases, the surgery is performed as a treatment for other underlying medical conditions, such as osteotomy. The surgery involves the fusion of the affected fingers with the rest of the fingers on the hand, which can help to improve function and appearance.

Another treatment option for OFD1 is the use of certain medications. One such medication is called \"propranolol,\" which is a beta-blocker that can help to reduce the risk of blood clots and other complications associated with the condition.

In addition to surgery and medication, there are also some lifestyle changes that can be made to help manage the symptoms of OFD1. For example, avoiding activities that put stress on the affected fingers, such as gripping objects, can help to reduce the risk of injury. Wearing protective clothing, such as gloves, can also help to reduce the risk of injury.

Overall, OFD1 is a rare and complex disorder that can cause a range of symptoms. While there are currently no cure options for the condition, there are a few treatment options available to help manage the symptoms and improve quality of life. If you are affected by OFD1, it is important to talk to a healthcare professional to determine the best course of treatment for your individual needs.

Protein Name: OFD1 Centriole And Centriolar Satellite Protein

Functions: Component of the centrioles controlling mother and daughter centrioles length. Recruits to the centriole IFT88 and centriole distal appendage-specific proteins including CEP164 (By similarity). Involved in the biogenesis of the cilium, a centriole-associated function. The cilium is a cell surface projection found in many vertebrate cells required to transduce signals important for development and tissue homeostasis (PubMed:33934390). Plays an important role in development by regulating Wnt signaling and the specification of the left-right axis. Only OFD1 localized at the centriolar satellites is removed by autophagy, which is an important step in the ciliogenesis regulation (By similarity)

The "OFD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OFD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OGA | OGDH | OGDHL | OGFOD1 | OGFOD2 | OGFOD3 | OGFR | OGFR-AS1 | OGFRL1 | OGFRP1 | OGG1 | OGN | OGT | OIP5 | OIP5-AS1 | OIT3 | OLA1 | OLA1P1 | OLAH | OLFM1 | OLFM2 | OLFM3 | OLFM4 | OLFML1 | OLFML2A | OLFML2B | OLFML3 | OLIG1 | OLIG2 | OLIG3 | Oligosaccharyltransferase complex | OLMALINC | OLR1 | OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2